Asterias Biotherapeutics Inc. Warrants (expiring September 29, 2017)

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch AST+ and buy or sell other stocks, ETFs, and their options commission-free!

About AST+

Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine. Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer. 

CEO
Brian M. Culley, MBA
CEOBrian M. Culley, MBA
Employees
—
Employees—
Headquarters
Carlsbad, California
HeadquartersCarlsbad, California
Founded
2012
Founded2012
Employees
—
Employees—

AST+ Key Statistics

Market cap
—
Market cap—
Price-Earnings ratio
—
Price-Earnings ratio—
Dividend yield
—
Dividend yield—
Average volume
—
Average volume—
High today
—
High today—
Low today
—
Low today—
Open price
—
Open price—
Volume
0.00
Volume0.00
52 Week high
—
52 Week high—
52 Week low
—
52 Week low—

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.